DIANT Pharma is a biopharma company with a proprietary continuous processing technology uniquely designed for nanoparticle drug products and vaccines. Formed in 2019, DIANT emerged from research at the University of Connecticut, and their goal is to optimize LNP production with continuous manufacturing. The company provides clients with their continuous manufacturing systems to produce lipid nanoparticles for delivering mRNA-based vaccines and therapeutics. DIANT sells systems for production at research- to commercial-scale, and they also provide custom R&D services of mRNA–LNP products.
